Trade Publication Article

PRIME: Sacubitril/valsartan shows benefits in mitral regurgitation

Fonarow, Gregg C, Swain, Erik

2019

Overview

The researchers conducted the PRIME doubleblind trial of 118 patients (mean age, 63 years; 61% men) with HF with reduced ejection fraction and chronic functional mitral regurgitation secondary to left ventricular dysfunction who were taking standard medical therapy for HF. \"Angiotensin receptor-neprilysin inhibitor may be considered for optimal medical therapy of stable patients with heart failure and functional mitral regurgitation,\" Kang and colleagues wrote. - by Erik Swain ? PERSPECTIVE Sacubitril/valsartan has been demonstrated to reduce CV death and HF hospitalizations superior to that of the ACE inhibitor enalapril in patients with HF with reduced ejection fraction. Sacubitril/valsartan is already class I recommended in national and international HF guidelines to further reduce morbidity and mortality in patients with HF with reduced ejection fraction who are NYHA class II or III. [...]irrespective of the presence or absence of functional mitral regurgitation, a compelling rationale for treatment with sacubitril/valsartan exists in eligible patients without contraindications.

• Publisher: SLACK INCORPORATED
• Subject: Cardiology / Researchers